The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

NCT03007446 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Apatinib
DRUG: Oxaliplatin
DRUG: S-1

Sponsor

Chinese PLA General Hospital